# Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.

> **NCT03798236** · PHASE1 · COMPLETED · sponsor: **Palobiofarma SL** · enrollment: 32 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** PBF-1650 oral capsules
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03798236
- **Lead sponsor:** Palobiofarma SL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-10
- **Primary completion:** 2019-03-30
- **Final completion:** 2019-05-31
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798236, "Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03798236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*